EMA Begins Rolling Review of Sanofi’s COVID-19 Vaccine
The European Medicines Agency (EMA) has begun a rolling review of Vidprevtyn, a COVID-19 vaccine candidate developed by Sanofi and GlaxoSmithKline (GSK).
The vaccine delivers a harmless version of the spike protein found on the surface of the SARS-CoV-2 virus that causes COVID-19 infections. It also includes an adjuvant from GSK that helps strengthen the immune response.
In the rolling review, the EMA will not wait for complete supporting data from the companies but will look at results as they become available so it can more quickly decide whether to authorize the product. Early trial results have shown the vaccine induces protective antibodies against the coronavirus.